Escient Pharmaceuticals

Escient Pharmaceuticals is a San Diego, California clinical-stage biopharmaceutical company developing first-in-class, oral small-molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) along the neurosensory-inflammatory axis. Its lead programs are EP262, an MRGPRX2 antagonist for mast-cell-mediated diseases such as chronic spontaneous and inducible urticaria and atopic dermatitis, and EP547, an MRGPRX4 antagonist for cholestatic and uremic pruritus. The company was backed by New Enterprise Associates (NEA) and was acquired by Incyte Corporation on May 30, 2024. Escient operates a corporate marketing website only and publishes no public API, developer program, or machine-readable API specification; this profile captures its identity and domain-security posture for the API Evangelist network.

Escient Pharmaceuticals is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Pharmaceuticals, Biotechnology, and Clinical Stage.

Escient Pharmaceuticals’ developer surface includes engineering blog, support, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub

15.0/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyLife SciencesPharmaceuticalsBiotechnologyClinical StageDrug DiscoveryImmunologyDermatology

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 15.0/100 · emerging

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/escient-pharmaceuticals: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: escient-pharmaceuticals
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/escient-pharmaceuticals.png
name: Escient Pharmaceuticals
description: Escient Pharmaceuticals is a San Diego, California clinical-stage biopharmaceutical company developing first-in-class,
  oral small-molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) along the neurosensory-inflammatory
  axis. Its lead programs are EP262, an MRGPRX2 antagonist for mast-cell-mediated diseases such as chronic spontaneous and
  inducible urticaria and atopic dermatitis, and EP547, an MRGPRX4 antagonist for cholestatic and uremic pruritus. The company
  was backed by New Enterprise Associates (NEA) and was acquired by Incyte Corporation on May 30, 2024. Escient operates a
  corporate marketing website only and publishes no public API, developer program, or machine-readable API specification;
  this profile captures its identity and domain-security posture for the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/escient-pharmaceuticals/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- nea
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Pharmaceuticals
- Biotechnology
- Clinical Stage
- Drug Discovery
- Immunology
- Dermatology
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/escient-pharmaceuticals-domain-security.yml
- type: Website
  url: https://www.escientpharma.com
- type: Blog
  url: https://www.escientpharma.com/news/
- type: Support
  url: https://www.escientpharma.com/contact/
- type: PrivacyPolicy
  url: https://www.escientpharma.com/privacy-policy/
- type: TermsOfService
  url: https://www.escientpharma.com/terms-of-use/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence